Suppr超能文献

低氧性呼吸衰竭患者自主觉醒试验后首次转换为压力支持通气失败:新型冠状病毒肺炎的影响

Failure of First Transition to Pressure Support Ventilation After Spontaneous Awakening Trials in Hypoxemic Respiratory Failure: Influence of COVID-19.

作者信息

Pérez Joaquin, Accoce Matías, Dorado Javier H, Gilgado Daniela I, Navarro Emiliano, Cardoso Gimena P, Telias Irene, Rodriguez Pablo O, Brochard Laurent

机构信息

Intensive Care Unit, Sanatorio Anchorena, San Martín, Buenos Aires, Argentina.

Intensive Care Unit, Hospital Carlos G. Durand, Ciudad Autónoma de Buenos Aires, Argentina.

出版信息

Crit Care Explor. 2023 Aug 25;5(9):e0968. doi: 10.1097/CCE.0000000000000968. eCollection 2023 Sep.

Abstract

OBJECTIVES

To describe the rate of failure of the first transition to pressure support ventilation (PSV) after systematic spontaneous awakening trials (SATs) in patients with acute hypoxemic respiratory failure (AHRF) and to assess whether the failure is higher in COVID-19 compared with AHRF of other etiologies. To determine predictors and potential association of failure with outcomes.

DESIGN

Retrospective cohort study.

SETTING

Twenty-eight-bedded medical-surgical ICU in a private hospital (Argentina).

PATIENTS

Subjects with arterial pressure of oxygen (AHRF to Fio [Pao/Fio] < 300 mm Hg) of different etiologies under controlled mechanical ventilation (MV).

INTERVENTIONS

None.

MEASUREMENTS AND MAIN RESULTS

We collected data during controlled ventilation within 24 hours before SAT followed by the first PSV transition. Failure was defined as the need to return to fully controlled MV within 3 calendar days of PSV start. A total of 274 patients with AHRF (189 COVID-19 and 85 non-COVID-19) were included. The failure occurred in 120 of 274 subjects (43.7%) and was higher in COVID-19 versus non-COVID-19 (49.7% and 30.5%; = 0.003). COVID-19 diagnosis (odds ratio [OR]: 2.22; 95% CI [1.15-4.43]; = 0.020), previous neuromuscular blockers (OR: 2.16; 95% CI [1.15-4.11]; = 0.017) and higher fentanyl dose (OR: 1.29; 95% CI [1.05-1.60]; = 0.018) increased the failure chances. Higher BMI (OR: 0.95; 95% CI [0.91-0.99]; = 0.029), Pao/Fio (OR: 0.87; 95% CI [0.78-0.97]; = 0.017), and pH (OR: 0.61; 95% CI [0.38-0.96]; = 0.035) were protective. Failure groups had higher 60-day ventilator dependence ( < 0.001), MV duration ( < 0.0001), and ICU stay ( = 0.001). Patients who failed had higher mortality in COVID-19 group ( < 0.001) but not in the non-COVID-19 ( = 0.083).

CONCLUSIONS

In patients with AHRF of different etiologies, the failure of the first PSV attempt was 43.7%, and at a higher rate in COVID-19. Independent risk factors included COVID-19 diagnosis, fentanyl dose, previous neuromuscular blockers, acidosis and hypoxemia preceding SAT, whereas higher BMI was protective. Failure was associated with worse outcomes.

摘要

目的

描述急性低氧性呼吸衰竭(AHRF)患者在系统的自主唤醒试验(SATs)后首次转换为压力支持通气(PSV)的失败率,并评估与其他病因的AHRF相比,新型冠状病毒肺炎(COVID-19)患者的失败率是否更高。确定失败的预测因素以及失败与预后的潜在关联。

设计

回顾性队列研究。

地点

一家私立医院(阿根廷)设有28张床位的内科-外科重症监护病房。

患者

在控制机械通气(MV)下不同病因的动脉血氧分压(AHRF,动脉血氧分压/吸入氧分数值[Pao/Fio]<300 mmHg)患者。

干预措施

无。

测量指标及主要结果

我们收集了SAT前24小时内控制通气期间的数据,随后进行首次PSV转换。失败定义为在PSV开始后3个日历日内需要恢复到完全控制的MV。共纳入274例AHRF患者(189例COVID-19患者和85例非COVID-19患者)。274例受试者中有120例(43.7%)发生失败,COVID-19患者的失败率高于非COVID-19患者(49.7%和30.5%;P = 0.003)。COVID-19诊断(比值比[OR]:2.22;95%置信区间[CI][1.15 - 4.43];P = 0.020)、先前使用神经肌肉阻滞剂(OR:2.16;95% CI[1.15 - 4.11];P = 0.017)和较高的芬太尼剂量(OR:1.29;95% CI[1.05 - 1.60];P = 0.018)增加了失败几率。较高体重指数(BMI)(OR:0.95;95% CI[0.91 - 0.99];P = 0.029)、Pao/Fio(OR:0.87;95% CI[0.78 - 0.97];P = 0.017)和pH值(OR:0.61;95% CI[0.38 - 0.96];P = 0.035)具有保护作用。失败组的60天呼吸机依赖率更高(P<0.001)、MV持续时间更长(P<0.0001)且ICU住院时间更长(P = 0.001)。失败患者在COVID-19组的死亡率更高(P<0.001),但在非COVID-19组则不然(P = 0.083)。

结论

在不同病因的AHRF患者中,首次PSV尝试的失败率为43.7%,COVID-19患者的失败率更高。独立危险因素包括COVID-19诊断、芬太尼剂量、先前使用神经肌肉阻滞剂、SAT前的酸中毒和低氧血症,而较高的BMI具有保护作用。失败与更差的预后相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a79e/10461949/30b52d6541a0/cc9-5-e0968-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验